Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients
“These are patients who had exhausted standard options, yet several remain on LP-184 with meaningful clinical benefit in challenging cancers one to two years later,” said Panna Sharma, CEO of Lantern Pharma. “This durability in genomically selected, end-stage cancer patients is encouraging and directly validates the predictive power of our RADR® AI platform and the PTGR1 biomarker. With a diagnostic-ready molecular assay for PTGR1, strong enthusiasm from key opinion leaders and multiple FDA designations in hand, Lantern plans on advancing LP-184 into multiple precision Phase 1b/2 trials targeting indications with aggregate annual U.S. market potential exceeding $10 to 12 billion.”
Share:
More News
“Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses,” said Jacob Van Naarden, executive vice president, and president of Lilly Oncology. “This Breakthrough Therapy designation reflects the early potential we’re seeing with
“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,” said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. “As we march the ATLAS trial forward and prepare for our 5th IND filing, these
“We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC. We designed IDE892 to be a potential best-in-class PRMT5 inhibitor, including approximately 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding, lack of brain penetrance, and favorable drug-like properties intended to maximize its therapeutic window as
“The data presented at ASCO provided important insight into the potential clinical path for CRB-701 in 2L oropharyngeal cancer, a distinct tumor-type that is on the rise due to HPV infections,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Unfortunately, current treatment options have shown limited efficacy underscoring the